BioMimetic Therapeutics Liabilities: 19.72M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
BMTI Liabilities Rankings
| Overall | 86th percentile | 607 of 4559 |
| Sector | 63rd percentile | 189 of 519 in Healthcare |
| Industry | 61st percentile | 25 of 65 in Medical Instruments & Supplies |
BMTI Liabilities Range, Past 5 Years
| Minimum | 20.39M | Dec 2006 |
| Maximum | 23.15M | Jun 2006 |
| Average | 21.81M |
About Total Liabilities
Liabilities are obligations of a company arising from past transactions or events which are expected to reduce assets when they are settled.
Total liabilities is a line item on the balance sheet.
Learn More
You may also be interested in these BMTI related companies
BMTI News
BioMimetic Therapeutics, Inc. to Introduce Augmatrix™ Biocomposite Bone Graft Product Line at AAOS
Feb 08, 9:25AM Business Wire
Feb 08, 9:25AM Business Wire
$BMTI too risky. Strong Buys $SINO,target $6 $ONTY $OCZ lots of room to run
about 5 days ago by contrarian1
about 5 days ago by contrarian1
Collins Stewart Reiterates a 'Buy' on BioMimetic Therapeutics (BMTI); Positive Pilot Study Offer Another Sizable Opportunity
Feb 07, 11:05AM Street Insider
Feb 07, 11:05AM Street Insider
Morning Movers 02/07: (SATC) (BMTI) (CSTR) (MNI) Higher; (ASTX) (ACHN) (BVSN) Lower
Feb 07, 11:00AM Street Insider
Feb 07, 11:00AM Street Insider
BioMimetic Therapeutics, Inc. to Highlight Product Development Activities at ORS and AAOS Meetings
Feb 06, 4:00PM Business Wire
Feb 06, 4:00PM Business Wire
BioMimetic Therapeutics, Inc. to Present at the 30th Annual J.P. Morgan Healthcare Conference
Jan 10, 11:00AM Business Wire
Jan 10, 11:00AM Business Wire
Wedbush Downgrades BioMimetic Therapeutics (BMTI) to Neutral, Still See Approval of Augment Bone Graft
Jan 04, 12:18PM Street Insider
Jan 04, 12:18PM Street Insider
$BMTI BioMimetic Therapeutics downgraded to Neutral from Outperform at Wedbush
about 39 days ago by _TheBlackSwan_
about 39 days ago by _TheBlackSwan_
BioMimetic (BMTI) Down as FDA Doesn't Approve Augment Bone Graft PMA in Current Form
Jan 03, 4:19PM Street Insider
Jan 03, 4:19PM Street Insider
BioMimetic (BMTI) Doesn't Get FDA Approval for Augment Bone Graft in Current Form
Jan 03, 4:15PM Street Insider
Jan 03, 4:15PM Street Insider
BioMimetic Therapeutics Announces Approval to Market GEM 21S in the European Union
Jan 03, 4:11PM Benzinga
Jan 03, 4:11PM Benzinga
BioMimetic Therapeutics Announces Approval to Market GEM 21S® in the European Union
Jan 03, 4:11PM Business Wire
Jan 03, 4:11PM Business Wire
BioMimetic Therapeutics Receives Augment Bone Graft PMA Response Letter from FDA
Jan 03, 4:04PM Benzinga
Jan 03, 4:04PM Benzinga
BioMimetic Therapeutics Receives Augment® Bone Graft PMA Response Letter from FDA
Jan 03, 4:04PM Business Wire
Jan 03, 4:04PM Business Wire
$BMTI http://stks.co/1LXu large directional move implied given ideal adx alignment, needs over $3.15 to snowball HT @stt2318
about 73 days ago by traderdigs
about 73 days ago by traderdigs
$BMTI Collins Stewart Starts BioMimetic Therapeutics at Buy http://stks.co/1Euy
about 82 days ago by ACInvestorBlog
about 82 days ago by ACInvestorBlog
$BMTI http://stks.co/1EtQ We are on the verge of a possible breakout in the shares of $BMTI.Upgraded this morning to BUY.PT $7
about 82 days ago by ACInvestorBlog
about 82 days ago by ACInvestorBlog
BioMimetic Therapeutics, Inc. Reports Third Quarter 2011 Earnings Results
Nov 08, 4:00PM Business Wire
Nov 08, 4:00PM Business Wire
BioMimetic Therapeutics, Inc. to Report 2011 Third Quarter Financial Results on November 8
Nov 04, 11:02AM Business Wire
Nov 04, 11:02AM Business Wire
BioMimetic $BMTI receives approval to commercialize Augment(R) Bone Graft in Australia
about 116 days ago by Street_Insider
about 116 days ago by Street_Insider
@ACInvestorBlog How do u feel about $BMTI ATM? Im long @ 2.99. Have any info besides technicals? What do u think breakout will look like?
about 122 days ago by JohnETownsend
about 122 days ago by JohnETownsend
$BMTI http://stks.co/aGq $K line has just crossed on top over $D line indicating buy signal. Nice bottom base here.
about 123 days ago by ACInvestorBlog
about 123 days ago by ACInvestorBlog
Potential upside of 303.4% exists for $BMTI .... lol ... nice post : http://stks.co/XXq
about 128 days ago by ACInvestorBlog
about 128 days ago by ACInvestorBlog
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BMTI | 2.13 | -0.10 | -4.48% | 59.73M |
| GASS | 4.35 | 0.03 | 0.66% | 91.78M |
| ICGE | 9.85 | -0.15 | -1.50% | 364.15M |
| DE | 87.55 | -0.38 | -0.43% | 36.24B |
| V | 113.90 | 1.48 | 1.32% | 92.60B |
| TV | 19.79 | -0.28 | -1.40% | 11.20B |
| DV | 38.56 | -0.28 | -0.72% | 2.59B |
| ERIC | 9.58 | 0.09 | 0.95% | 30.72B |
| ITRI | 41.45 | -0.96 | -2.28% | 1.69B |
| AAP | 79.99 | -0.13 | -0.16% | 6.13B |